【醫學】抑制PCSK9可以有效降低膽固醇

基因名稱：proprotein convertase subtilisin/kexin type 9 (PCSK9)
介紹

1. Genetics Home Reference
   PCSK9
2. OMIM
   PROPROTEIN CONVERTASE, SUBTILISIN/KEXIN-TYPE, 9; PCSK9

新聞

1. Reuters
   (Mar. 25, 2012) Monthly shots of Amgen drug slash cholesterol up to 66 percent
   (Mar. 26, 2012) Regeneron cholesterol drug faces sudden challenge
2. 中時電子報
   (Mar. 26, 2012) 降膽固醇新藥 估年銷250億美元

期刊文章

1. Nature Genetics｜Brief communication
   (May. 5, 2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
2. NEJM｜Original article
   (Mar. 23, 2006) Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
3. Nature SciBX｜Cover story
   (Jun. 4, 2009) The secreted secret of PCSK9
• Figure 1: PCSK9-mediated regulation of LDL receptor levels.（機轉圖）
4. Atherosclerosis｜Review
   (Apr. 22, 2011) Clinical aspects of PCSK9（完整介紹）
5. Nat Rev Cardiol｜Review
   (May. 2011) Pharmacological strategies for lowering LDL cholesterol: statins and beyond
• FIGURE 3 | Mechanisms of PCSK9 action.
• TABLE 4 | PCSK9 inhibitors under development
6. Nat Rev Drug Discov｜News and Analysis
   (Jan. 2012) Trial Watch: PCSK9 antibody reduces LDL cholesterol
• Supplementary table 1: Selected PCSK9-targeted therapies that are in development
7. MTNA｜Commentary
   (Jan. 31, 2012) Targeting LDL Cholesterol With LNA（siRNA藥物）
• Molecular Therapy｜Original article
  (Nov. 22, 2011) PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates（反股核醣核酸藥物，靈長類實驗）
8. NEJM｜Original article
   (Mar. 22, 2012) Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol（單株抗體藥物，人體試驗）
9. Nat Biotechnol｜News
   (Apr. 10, 2012) Biologics inch toward cholesterol-lowering market
• Table 1: Biologics targeting PCSK9 for hypercholesterolemia（進行中的臨床試驗）

藥廠資訊

1. Alnylam − Calpella（研發RNAi藥物）
• (Mar. 1, 2012) Delivery Strategies for RNAi Therapeutics
• (Apr. 20, 2012) Positive Clinical Results for ALN-PCS, Reported at ATVB 2012